Safety and IOP-Lowering Effects of WB007

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one eye. Part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of WB007 (selected based on Part 1 results) in both eyes compared with timolol 0.5% for 14 days.
Epistemonikos ID: 1d2eed5c0d7a560bab3ccac9b02a2e6438f71d06
First added on: May 06, 2024